Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar - CNBC
AI Summary1 min read
TL;DR
Eli Lilly exceeded earnings estimates and raised its 2025 guidance, driven by strong sales of Zepbound and Mounjaro weight loss drugs, boosting its stock price.
Tags
Eli LillyZepboundMounjaroearningsguidance
- Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar CNBC
- Eli Lilly Stock Rises on Earnings and Boost to Guidance Barron's
- Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance Yahoo Finance
- Lilly Raises Guidance on Strength of Weight Loss, Obesity Drugs Bloomberg.com
- Eli Lilly stock pops on raised full-year outlook (LLY:NYSE) Seeking Alpha